MYIG Stock Overview
Mydecine Innovations Group Inc., a biotechnology company, engages in the development and commercialization of psilocybin products for treating mental health problems.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Mydecine Innovations Group Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.018 |
| 52 Week High | US$0 |
| 52 Week Low | US$0 |
| Beta | 2.97 |
| 1 Month Change | 0% |
| 3 Month Change | 0% |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -82.50% |
Recent News & Updates
Recent updates
Shareholder Returns
| MYIG | GB Pharmaceuticals | GB Market | |
|---|---|---|---|
| 7D | 0% | 3.1% | 2.5% |
| 1Y | n/a | 7.9% | 6.1% |
Return vs Industry: Insufficient data to determine how MYIG performed against the UK Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how MYIG performed against the UK Market.
Price Volatility
| MYIG volatility | |
|---|---|
| MYIG Average Weekly Movement | 0% |
| Pharmaceuticals Industry Average Movement | 7.9% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in GB Market | 11.4% |
| 10% least volatile stocks in GB Market | 2.7% |
Stable Share Price: MYIG has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine MYIG's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2013 | 3 | Josh Bartch | www.mydecine.com |
Mydecine Innovations Group Inc., a biotechnology company, engages in the development and commercialization of psilocybin products for treating mental health problems. The company primarily focuses on treating smoking cessation. Its lead product drug candidates include MYCO-001, MYCO-002, MYCO003, and MYCO-004.
Mydecine Innovations Group Inc. Fundamentals Summary
| MYIG fundamental statistics | |
|---|---|
| Market cap | UK£261.27k |
| Earnings (TTM) | -UK£10.55m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.1x
P/E RatioIs MYIG overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MYIG income statement (TTM) | |
|---|---|
| Revenue | CA$0 |
| Cost of Revenue | CA$0 |
| Gross Profit | CA$0 |
| Other Expenses | CA$18.07m |
| Earnings | -CA$18.07m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.29 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | -84.4% |
How did MYIG perform over the long term?
See historical performance and comparison